Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist, and Executive Director of Employer Services at the City of Hope Comprehensive Cancer Center in Duarte, CA.

Upcoming TweetChat: Does the Lung Cancer Community Risk Losing Unity by Breaking Into Subgroups?
Wed, 08/07/2013 - 06:30
Author
Howard (Jack) West, MD, Associate Clinical Professor, Medical Oncology, Executive Director, Employer Services, Founder, President and CEO of GRACE

A couple of weeks ago, I described the new concept of a "tweetchat" about lung cancer, and we're about to have our second of these tomorrow: Thursday, August 8th, at 8 PM Eastern, 5 PM Pacific time. The topic for this one will be about the growing trend toward personalized cancer care, breaking what was previously one broad category of "lung cancer" into a federation of smaller subgroups -- defined by tumor histology, molecular marker results, smoking status, etc.  But do we risk losing some hard fought unity by identifying "us" and "them" subgroups within the lung cancer community?  Or can we subgroups who still come together toward a common goal of promoting lung cancer awareness, funding, and breakdown of stigma associated with the disease?

Specifically, we're going to cover three subtopics that have led to identification of subgroups and the potential implications of this.  First, let's consider smoking status, which certainly has biological relevance in predicting the probability of having certain clinically relevant molecular markers, but it's also an emotionally charged variable. Lung cancer awareness campaigns often highlight that some victims of lung cancer never smoked, since so many people blame the victim with lung cancer as if they deserve it for smoking.  Does this approach risk pitting smokers against never-smokers? Have we created antagonism within the lung cancer community between smokers and never-smoker, or is that increasingly likely as we focus on smoking status? Does the distinction of smoking status, which is relevant with regard to the biology of the cancer, cause people who smoked or continue to smoke feel worse?

Second, we've recently identified several important molecular markers present in only a small minority (1-10%) of lung cancer patients. In many cases, these have developed into major treatment advances, but just for these narrow patient subgroups.  By testing for and identifying patients as having or not having an EGFR mutation, ALK rearrangement, etc., are we developing a lung cancer world of "haves" and "have nots"?

Finally, we now face the challenge of doing clinical trials in small subgroups that don't have a critical mass of patients all in the same city or region with, say, an ALK or ROS1 rearrangement. We used to run broad trials for "all people with advanced non-small cell lung cancer" who have received a single line of chemotherapy.  How can we feasibly do studies where there might be just 1-5 people in a single area who fit the requirements. Do those people with a rare mutation or acquired resistance to EGFR inhibitors, etc., need to travel to the handful of locations that have such trials? How can we best facilitate such trials being completed and new treatments becoming available for geographically dispersed small subgroups?

For those of you who already participate on Twitter and are able to join our live tweetchat, please join the conversation tomorrow: just filter for the hashtag "#lcsm",follow the stream of comments that come in, and add that hashtag to your tweets.  Otherwise, your insights and opinions would be very appreciated on all of these questions, whether before or after the live tweetchat, and I'd encourage you to share them here.  

Next Previous link

Previous PostNext Post

Related Content

Forum Discussions

Hi JGromo, Welcome to Grace. I'm so sorry your dad and by extension, you are going through this. If it helps, I know how you feel. My husband is going through...

I agree that not all docs are good communicators! Remember they are people just like us, filling a very important role. I echo Janine's comment to ask questions here -- our...

While no one can give advice or recommend treatments on a forum our faculty can be invaluable when talking about current thought and practices.


 


This is the response via email...

From Dr. West, He reminds us, "The principle is not to over-react to minimal change." and suggests this article and the ones on oligoprogression linked in the above post.  "Note in...

Hi Sean,


Welcome to Grace. I'm so sorry you're going through this. I can only imagine your worry about metastases and I hope that's not the case.
Liver hemangiomas are thought...

n3p, Hi and welcome to Grace. I'm sorry you have to check for new nodules. It does sound like your onc has good reason not to be alarmed that you have...

Thanks for the thoughtful response, I really appreciate that! All your points make sense. I will check back in later.

Recent Comments

JOIN THE CONVERSATION
From Dr. West, He reminds us…
By JanineT Forum … on Tue, 02/07/2023 - 19:49
This is the response via…
By JanineT Forum … on Tue, 02/07/2023 - 19:02
I agree that not all docs…
By JanineT Forum … on Tue, 02/07/2023 - 18:21
Hi JGromo, Welcome to Grace…
By JanineT Forum … on Mon, 02/06/2023 - 14:44